MURA (Mural Oncology) NonCurrent Deferred Liabilities : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Mural Oncology's non-current deferred liabilities for the quarter that ended in Mar. 2025 was $0.00 Mil.

Mural Oncology NonCurrent Deferred Liabilities Historical Data

The historical data trend for Mural Oncology's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology NonCurrent Deferred Liabilities Chart

Mural Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

NonCurrent Deferred Liabilities

Mural Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial							-	-	-	-	-

Mural Oncology NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Mural Oncology's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Mural Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.muraloncology.com

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.